INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...

Eli Lilly and Co. has won U.S. regulatory approval to market its slow-selling osteoporosis drug Forteo for a new use, Lilly announced today. Lilly can now promote Forteo as a therapy for men and women ...

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented a study that assessed the effects of 18 months of treatment with FORTEO ® (teriparatide [rDNA origin] ...

INDIANAPOLIS, Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that a total of 14 U.S. and global studies involving its ...

In a head-to-head comparison of the two drugs, Forteo increased lumbar spine density measurements by 7.2 percent compared to 3.4 percent for Fosamax, and it boosted hip density measurements by 3.8 ...

The clutter in my parents' kitchen sometimes gives me clues about their health that I don't get through more direct means. When either of them gets sick, for instance, the counter usually reserved for ...

Forteo (teriparatide) is a brand-name drug that doctors prescribe for some people with osteoporosis. It contains proteins that strengthen bones and stimulate new bone growth. A typical prescription is ...

The FDA has approved its NDA for PF708 under the 505(b)(2) regulatory pathway, with Amgen, Inc. AMGN's Forteo as the reference drug. PF708 has been indicated to treat osteoporosis in certain patients ...